Acute exacerbation of interstitial lung disease after procedures - 08/04/19
Abstract |
Interstitial lung disease (ILD) is a category of diffuse parenchymal lung diseases characterized by inflammation and/or fibrosis. The best characterized ILD is idiopathic pulmonary fibrosis (IPF). Acute exacerbation of IPF is a dreaded occurrence with grim prognosis and suboptimal treatment options. There have been recent reports that acute exacerbation can occur in other ILDs (AE-ILD). Of note, some of these acute exacerbations follow lung procedures. This review summarizes the available information on AE-ILD and discusses the procedures reported to cause AE-ILD. We also discuss proposed mechanisms, risk factors, treatment and prognosis. This review should help to inform decision-making about risks versus benefits of procedures that are commonly recommended to diagnose ILD.
Le texte complet de cet article est disponible en PDF.Highlights |
• | We propose to define AE-ILD using the same criteria as AE-IPF. |
• | Prognosis of AE-ILD is very poor. |
• | Acute exacerbations of ILD can occur after bronchoscopic and surgical procedures. |
• | Hyperoxia, single lung ventilation, infection or aspiration are hypothesized mechanisms that lead to AE-ILD after procedures. |
• | Corticosteroids are most commony used to treat AE-ILD. |
Keywords : Acute exacerbation of interstitial lung disease, Acute exacerbation, Interstitial lung disease, AE-ILD, Lung biopsy
Plan
Vol 150
P. 30-37 - avril 2019 Retour au numéro
- Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma
- Paraskevi Katsaounou, Roland Buhl, Guy Brusselle, Pascal Pfister, Rafael Martínez, Ulrich Wahn, Jean Bousquet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?